New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
11:04 EDTOII, PPHM, TSM, XPO, ASHHigh option volume stocks: PPHM ASH TSM OII XPO
News For PPHM;ASH;TSM;OII;XPO From The Last 14 Days
Check below for free stories on PPHM;ASH;TSM;OII;XPO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
17:08 EDTOIIOceaneering backs FY14 $3.90-$4.10, consensus $4.03
Subscribe for More Information
17:08 EDTOIIOceaneering sees Q2 EPS 97c-$1.01, consensus $1.04
Subscribe for More Information
17:06 EDTOIIOceaneering reports Q1 EPS 84c, consensus 80c
Subscribe for More Information
17:02 EDTOIIOceaneering International increases quarterly dividend
Oceaneering International announced that its board declared a regular quarterly dividend of 27c per common share, an increase from its prior quarterly dividend of 22c per share. The dividend is payable June 20 to shareholders of record at the close of business on May 30.
07:37 EDTPPHMPeregrine announces investigator-sponsored combination trial with Bristol-Myers
Peregrine Pharmaceuticals (PPHM) announced the opening of an investigator-sponsored trial, or IST, of its investigational immunotherapy bavituximab in combination with Bristol-Myers Squibb's (BMY) ipilimumab, for the treatment of advanced melanoma. Bavituximab is an upstream immune checkpoint inhibitor that targets phosphatidylserine, or PS, a highly immunosuppressive molecule exposed on cells that line tumor blood vessels and tumor cells. Preclinical data in a model of melanoma demonstrate that the combination of a bavituximab equivalent and ipilimumab yield enhanced anti-tumor activity compared to ipilimumab alone. The trial is being conducted at the University of Texas Southwestern Medical Center, Dallas, and led by Arthur E. Frankel, M.D., Associate Professor of Internal Medicine at the Simmons Comprehensive Cancer Center. Bavituximab, Peregrine's lead immuno-oncology candidate, is being evaluated in second-line non-small cell lung cancer, as part of the SUNRISE pivotal Phase III clinical trial.
April 22, 2014
10:00 EDTTSMOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: CommonWealth REIT (CWH) downgraded to Sell from Hold at Stifel... Del Frisco's (DFRG) downgraded to Market Perform from Outperform at Raymond James... Deutsche Bank (DB) downgraded to Neutral from Buy at UBS... Diageo (DEO) downgraded to Market Perform from Outperform at Raymond James... Eni SpA (E) downgraded to Neutral from Buy at UBS... Fidelity & Guaranty Life (FGL) downgraded to Neutral from Outperform at Credit Suisse... Frontier Communications (FTR) downgraded to Hold from Buy at Gabelli... QEP Resources (QEP) downgraded to Equalweight from Overweight at Barclays... Rogers Communications (RCI) downgraded to Sell from Hold at Canaccord... Rush Enterprises (RUSHA) downgraded to Underperform from Buy at BofA/Merrill... TSMC (TSM) downgraded to Neutral from Overweight at HSBC... Valero (VLO) downgraded to Neutral from Buy at BofA/Merrill... Wisconsin Energy (WEC) downgraded to Fair Value from Buy at CRT Capital... Zillow (Z) downgraded to Fair Value from Buy at CRT Capital... Zions Bancorp (ZION) downgraded to Equal Weight from Overweight at Evercore.
08:12 EDTTSMTSMC downgraded to Neutral from Overweight at HSBC
Subscribe for More Information
07:48 EDTASHAshland Chairman, CEO James O'Brien to retire in December
Subscribe for More Information
April 21, 2014
06:51 EDTTSMTSMC to ramp IC packaging revenue to $2B in 2016, DigiTimes reports
Subscribe for More Information
05:03 EDTTSMAltera, TSMC announces collaboration
Subscribe for More Information
April 17, 2014
12:01 EDTTSMTSMC climbs after profit beats expectations
Subscribe for More Information
11:39 EDTTSMTSMC upgraded to Buy from Neutral at UBS
Subscribe for More Information
06:45 EDTTSMTSMC foresees sales exceeding projections on mobile demand, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use